Liver Transplantation (HBV Infection)

Drug Combination Prevents Reinfection

Published in Hepatitis Weekly, January 17th, 2000

A combination of lamivudine and low-dose hepatitis B immune globulin (HBIG) can prevent allograft reinfection in chronic hepatitis B virus (HBV) patients after liver transplants, reported researchers from Canada.

"Current protocols for prophylaxis against allograft reinfection after liver transplantation for chronic HBV infection include the administration of large doses of HBIG, with considerable associated costs. Monotherapeutic prophylaxis with lamivudine has been complicated by the development of resistant strains of HBV," wrote E. M. Yoshida, of the Vancouver Hospital and Health Science Center, and colleagues.

The researchers administered a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-01-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry